vs
AETHLON MEDICAL INC（AEMD）与Apyx Medical Corp（APYX）财务数据对比。点击上方公司名可切换其他公司
Apyx Medical Corp的季度营收约是AETHLON MEDICAL INC的319.6倍（$19.2M vs $60.0K）。Apyx Medical Corp净利率更高（-6.8% vs -2926.4%，领先2919.6%）。AETHLON MEDICAL INC自由现金流更多（$-2.0M vs $-2.8M）
AETHLON MEDICAL INC是一家临床阶段医疗科技企业，专注开发针对性治疗类医疗器械，核心产品血液净化器可从血液中去除有害病毒、肿瘤外泌体及其他病原体，业务聚焦传染病和肿瘤治疗赛道，主要市场覆盖北美地区。
Apyx Medical前身是博维医疗，是美国的医疗器械制造商，专注生产电外科产品与能源技术相关医疗设备，公司总部位于佛罗里达州克利尔沃特，在保加利亚设有生产工厂。
AEMD vs APYX — 直观对比
营收规模更大
APYX
是对方的319.6倍
$60.0K
净利率更高
APYX
高出2919.6%
-2926.4%
自由现金流更多
AEMD
多$792.0K
$-2.8M
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $60.0K | $19.2M |
| 净利润 | $-1.8M | $-1.3M |
| 毛利率 | — | 62.6% |
| 营业利润率 | -3026.4% | 0.1% |
| 净利率 | -2926.4% | -6.8% |
| 营收同比 | — | 34.7% |
| 净利润同比 | 49.4% | 71.9% |
| 每股收益（稀释后） | $-10.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AEMDAPYX
| Q4 25 | — | $19.2M | ||
| Q3 25 | — | $12.9M | ||
| Q2 25 | — | $11.4M | ||
| Q1 25 | — | $9.4M | ||
| Q4 24 | $60.0K | $14.2M | ||
| Q3 24 | $95.1K | $11.5M | ||
| Q2 24 | — | $12.1M | ||
| Q1 24 | — | $10.2M |
净利润AEMDAPYX
| Q4 25 | — | $-1.3M | ||
| Q3 25 | — | $-2.0M | ||
| Q2 25 | — | $-3.8M | ||
| Q1 25 | — | $-4.2M | ||
| Q4 24 | $-1.8M | $-4.6M | ||
| Q3 24 | $-2.8M | $-4.7M | ||
| Q2 24 | — | $-6.6M | ||
| Q1 24 | — | $-7.6M |
毛利率AEMDAPYX
| Q4 25 | — | 62.6% | ||
| Q3 25 | — | 64.4% | ||
| Q2 25 | — | 62.3% | ||
| Q1 25 | — | 60.1% | ||
| Q4 24 | — | 63.0% | ||
| Q3 24 | — | 60.5% | ||
| Q2 24 | — | 61.7% | ||
| Q1 24 | — | 58.1% |
营业利润率AEMDAPYX
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | -6.5% | ||
| Q2 25 | — | -22.6% | ||
| Q1 25 | — | -32.4% | ||
| Q4 24 | -3026.4% | -21.4% | ||
| Q3 24 | -3050.2% | -31.6% | ||
| Q2 24 | — | -45.7% | ||
| Q1 24 | — | -64.6% |
净利率AEMDAPYX
| Q4 25 | — | -6.8% | ||
| Q3 25 | — | -15.4% | ||
| Q2 25 | — | -33.2% | ||
| Q1 25 | — | -44.0% | ||
| Q4 24 | -2926.4% | -32.5% | ||
| Q3 24 | -2950.2% | -40.9% | ||
| Q2 24 | — | -54.0% | ||
| Q1 24 | — | -74.0% |
每股收益（稀释后）AEMDAPYX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-10.05 | — | ||
| Q3 24 | $-16.11 | — | ||
| Q2 24 | — | $-0.19 | ||
| Q1 24 | — | $-0.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.8M | $31.7M |
| 总债务越低越好 | — | $37.5M |
| 股东权益账面价值 | $4.3M | $14.5M |
| 总资产 | $6.5M | $66.8M |
| 负债/权益比越低杠杆越低 | — | 2.58× |
8季度趋势，按日历期对齐
现金及短期投资AEMDAPYX
| Q4 25 | — | $31.7M | ||
| Q3 25 | — | $25.1M | ||
| Q2 25 | — | $29.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | $4.8M | $31.7M | ||
| Q3 24 | $6.9M | $28.0M | ||
| Q2 24 | — | $32.7M | ||
| Q1 24 | — | $37.3M |
总债务AEMDAPYX
| Q4 25 | — | $37.5M | ||
| Q3 25 | — | $37.5M | ||
| Q2 25 | — | $37.5M | ||
| Q1 25 | — | $37.5M | ||
| Q4 24 | — | $37.5M | ||
| Q3 24 | — | $37.5M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益AEMDAPYX
| Q4 25 | — | $14.5M | ||
| Q3 25 | — | $5.8M | ||
| Q2 25 | — | $7.3M | ||
| Q1 25 | — | $10.5M | ||
| Q4 24 | $4.3M | $14.2M | ||
| Q3 24 | $6.0M | $11.0M | ||
| Q2 24 | — | $14.7M | ||
| Q1 24 | — | $20.3M |
总资产AEMDAPYX
| Q4 25 | — | $66.8M | ||
| Q3 25 | — | $57.4M | ||
| Q2 25 | — | $58.2M | ||
| Q1 25 | — | $60.2M | ||
| Q4 24 | $6.5M | $64.8M | ||
| Q3 24 | $8.8M | $60.7M | ||
| Q2 24 | — | $65.4M | ||
| Q1 24 | — | $70.7M |
负债/权益比AEMDAPYX
| Q4 25 | — | 2.58× | ||
| Q3 25 | — | 6.41× | ||
| Q2 25 | — | 5.17× | ||
| Q1 25 | — | 3.57× | ||
| Q4 24 | — | 2.64× | ||
| Q3 24 | — | 3.40× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.0M | $-2.5M |
| 自由现金流经营现金流 - 资本支出 | $-2.0M | $-2.8M |
| 自由现金流率自由现金流/营收 | -3357.0% | -14.6% |
| 资本支出强度资本支出/营收 | 3.7% | 1.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-9.1M |
8季度趋势，按日历期对齐
经营现金流AEMDAPYX
| Q4 25 | — | $-2.5M | ||
| Q3 25 | — | $-3.5M | ||
| Q2 25 | — | $-1.2M | ||
| Q1 25 | — | $-702.0K | ||
| Q4 24 | $-2.0M | $-2.9M | ||
| Q3 24 | $-2.2M | $-4.4M | ||
| Q2 24 | — | $-4.3M | ||
| Q1 24 | — | $-6.3M |
自由现金流AEMDAPYX
| Q4 25 | — | $-2.8M | ||
| Q3 25 | — | $-4.1M | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-757.0K | ||
| Q4 24 | $-2.0M | $-3.2M | ||
| Q3 24 | — | $-4.6M | ||
| Q2 24 | — | $-4.6M | ||
| Q1 24 | — | $-6.4M |
自由现金流率AEMDAPYX
| Q4 25 | — | -14.6% | ||
| Q3 25 | — | -31.5% | ||
| Q2 25 | — | -13.2% | ||
| Q1 25 | — | -8.0% | ||
| Q4 24 | -3357.0% | -22.4% | ||
| Q3 24 | — | -40.0% | ||
| Q2 24 | — | -38.0% | ||
| Q1 24 | — | -62.2% |
资本支出强度AEMDAPYX
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 4.0% | ||
| Q2 25 | — | 2.3% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | 3.7% | 1.7% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 0.3% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
